# Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

> **NCT01742286** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 83 (actual)

## Conditions studied

- ALK-activated Tumors

## Interventions

- **DRUG:** Ceritinib

## Key facts

- **NCT ID:** NCT01742286
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-28
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01742286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01742286, "Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01742286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*